Engineered microtissues for the bystander therapy against cancer
Cita com:
hdl:2117/362135
Tipus de documentArticle
Data publicació2021-02-01
EditorElsevier
Condicions d'accésAccés obert
Llevat que s'hi indiqui el contrari, els
continguts d'aquesta obra estan subjectes a la llicència de Creative Commons
:
Reconeixement-NoComercial-SenseObraDerivada 3.0 Espanya
Abstract
Thymidine kinase expressing human adipose mesenchymal stem cells (TK-hAMSCs) in combination with ganciclovir (GCV) are an effective platform for antitumor bystander therapy in mice models. However, this strategy requires multiple TK-hAMSCs administrations and a substantial number of cells. Therefore, for clinical translation, it is necessary to find a biocompatible scaffold providing TK-hAMSCs retention in the implantation site against their rapid wash-out. We have developed a microtissue (MT) composed by TKhAMSCs and a scaffold made of polylactic acid microparticles and cell-derived extracellular matrix deposited by hAMSCs. The efficacy of these MTs as vehicles for TK-hAMSCs/GCV bystander therapy was evaluated in a rodent model of human prostate cancer. Subcutaneously implanted MTs were integrated in the surrounding tissue, allowing neovascularization and maintenance of TK-hAMSCs viability. Furthermore, MTs implanted beside tumors allowed TK-hAMSCs migration towards tumor cells and, after GCV administration, inhibited tumor growth. These results indicate that TK-hAMSCs-MTs are promising cell reservoirs for clinical use of therapeutic MSCs in bystander therapies.
CitacióBlanco Fernández, B. [et al.]. Engineered microtissues for the bystander therapy against cancer. "Materials science & engineering. C, Biomimetic materials, sensors and systems", 1 Febrer 2021, vol. 121, p. 1111854:1-111854:13.
ISSN1873-0191
Versió de l'editorhttps://www.sciencedirect.com/science/article/abs/pii/S0928493120337735
Fitxers | Descripció | Mida | Format | Visualitza |
---|---|---|---|---|
PostPrint ByStander therapy.pdf | 1,495Mb | Visualitza/Obre | ||
By stander treatment.pdf | 1,539Mb | Visualitza/Obre |